You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Dow
Baxter
AstraZeneca
McKesson

Last Updated: January 20, 2021

DrugPatentWatch Database Preview

Litigation Details for Merck Sharp & Dohme Corp. v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Merck Sharp & Dohme Corp. v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)

Docket   Start Trial Date Filed 2014-07-03
Court District Court, D. Delaware Date Terminated 2016-11-16
Cause 35:271 Patent Infringement Assigned To Sue Lewis Robinson
Jury Demand None Referred To Sherry R. Fallon
Parties APOTEX INC.; MERCK SHARP & DOHME CORP.; TEVA PHARMACEUTICALS USA INC.
Patents 6,127,353
Attorneys Andrew E. Riley; Aviv Zalcenstein; Bindu Ann George Palapura; David Ellis Moore; David M. Hashmall; Derek James Fahnestock; Frederick H. Rein; Ira J. Levy; Jack B. Blumenfeld; John C. Phillips , Jr.; Joseph B. Crystal; Joshua A. Whitehill; Joshua P. Davis; Lindsay M. Volpenhein; Lisa M. Thomas; Michael B. Cottler; Michelle J. Eber; Nicolas G. Barzoukas; Richard L. Horwitz
Firms Morris, Nichols, Arsht & Tunnell; Phillips, Goldman, McLaughlin & Hall, P.A.
Link to Docket External link to docket
Small Molecule Drugs cited in Merck Sharp & Dohme Corp. v. Teva Pharmaceuticals USA Inc.
The small molecule drug covered by the patent cited in this case is   Start Trial .

Details for Merck Sharp & Dohme Corp. v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)

Date Filed Document No. Description Snippet Link To Document
2015-09-03 132 alleging infringement of U.S. Patent No. 6, 127,353 ("the '353 patent") ("New Jersey/…henceforth will be to Civ. No. 14-874. to work on patent infringement litigation "relating to the drug…Merck failed to prove infringement of the '353 patent and dismissed Merck's claims. (Id., ex. 7A)…July 2014, asserting infringement of the '353 patent. Merck instituted Civ. No. 15-250 against defendant…March 2015, asserting infringement of the '353 patent. Also in March 2015, Merck instituted a second External link to document
2015-09-03 133 disputed claim language of U.S. Patent No. 6,127,353 ("the '353 patent") shall be construed…quot;Mometasone furoate monohydrate." The patented invention "relates to the novel compound… 16 November 2016 1:14-cv-00874 830 Patent None District Court, D. Delaware External link to document
2015-11-24 149 Victor Young Regarding Infringement of U.S. Patent No. 6,127,353 filed by Merck Sharp & Dohme Corp..(Fahnestock… 16 November 2016 1:14-cv-00874 830 Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
Medtronic
Moodys
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.